Eytan M. Stein, MD

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Eytan M. Stein, MD, discusses trials evaluating Menin inhibitors for patients with acute leukemia and unmet needs that persist in the space.

Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.

Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.

Eytan M. Stein, MD, discusses the unmet needs and challenges for treating patients with acute myeloid leukemia.

Eytan M. Stein, MD, discusses the currently available treatment options for patients with acute myeloid leukemia and how Menin inhibitors fit into this space.

Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.

Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.

Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.

Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.

Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.

Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.

Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.

Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.

Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Experts explain the goals of treatment for acute myeloid leukemia and the challenges presented.

Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant <em>IDH-2</em> relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.